Sabcomeline (Memric; SB-202,026) is a selective M<sub>1</sub> receptor partial agonist that was under development for the treatment of Alzheimer's disease. It made it to phase III clinical trials before being discontinued due to poor results.
It is a non-selective agonist of all five muscarinic acetylcholine receptors with similar affinities. However, functional selectivity for the M<sub>1</sub> receptor has been claimed in vitro and in vivo.